News & Updates

Show Multimedia Only

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Stepping up to triple therapy with inhaled corticosteroid (ICS) plus a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for patients with chronic obstructive pulmonary disease (COPD) inadequately controlled with dual therapy. The use of single-inhaler therapy has also been recommended over the use of multiple inhalers, as convenience has been associated with better treatment adherence and effectiveness. This article highlights the results of the first real-world comparative effectiveness study of two single-inhaler triple therapy (SITT) formulations, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and budesonide/ glycopyrrolate/formoterol fumarate (BUD/GLY/FORM), in patients who stepped up from prior dual combination therapy.

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

16 Sep 2025

Ruxolitinib: The first and only US FDA–approved topical repigmentation treatment for vitiligo

11 Sep 2025 by

Vitiligo, a chronic autoimmune condition characterized by skin depigmentation, significantly impacts patients’ quality of life (QoL) and psychosocial well-being. At a symposium held during the Advances in Medicine (AIM) 2025 conference, Dr Chau-Yee Ng of the Vitiligo Clinic and Pigment Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan, shared latest advances in vitiligo research, highlighting US FDA’s approval of ruxolitinib cream (Lumirix^®, Rxilient Medical), the first topical Janus kinase (JAK) inhibitor designed to target repigmentation in vitiligo.

Ruxolitinib: The first and only US FDA–approved topical repigmentation treatment for vitiligo

11 Sep 2025

Gender-neutral HPV vaccination – an important emerging need

21 Aug 2025 by

The increasing incidence of human papillomavirus (HPV)–related diseases in males over recent years is turning the spotlight on gender-neutral vaccination (GNV) to prevent HPV-related diseases and cancers in both sexes. Professor Hung-Hsueh Chou from the National Tsing Hua University, Hsinchu, Taiwan, and Dr Mike Yat-Wah Kwan, President of the Asian Society for Pediatric Infectious Diseases (ASPID), and other experts in Hong Kong shared insights on the need for gender-neutral HPV vaccination, as well as possible ways to overcome vaccination barriers and bridge the gender gap.

Gender-neutral HPV vaccination – an important emerging need

21 Aug 2025

Advancing collaboration in COVID-19 care

16 Aug 2025

Held in June 2025 in Singapore, the Pfizer COVID-CONNECT Masterclass convened international experts to discuss the evolving challenges of COVID-19. Co-chaired by Dr Asok Kurup and Dr Luke Moore, this event assessed the ongoing global impact of the disease and explored evidence-based strategies across the patient journey from early identification to effective treatment.

Advancing collaboration in COVID-19 care

16 Aug 2025

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

At the recent COVID-CONNECT Masterclass, an expert-led session explored where COVID-19 stands among common viral infections today. In a non-promotional symposium supported by Pfizer, infectious disease specialist Dr Leong Hoe Nam, Mount Elizabeth Hospital Novena, Singapore, discussed strategies for managing viral infections and surge preparedness. Complementing this, Professor David Strain from the University of Exeter Medical School, UK highlighted the enduring burden of long COVID.

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

15 Aug 2025

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

12 Jun 2025

Use of an SGLT2 inhibitor in an elderly patient with CKM syndrome and polypharmacy

23 Apr 2025 by

An 82-year-old frail Chinese male patient with multimorbidity and polypharmacy was admitted to the rehabilitation ward in November 2024 due to prior ischaemic stroke and congestive heart failure (HF) requiring treatment with oxygen and furosemide. Focused cardiac ultrasound (FoCUS) showed a left ventricular ejection fraction (LVEF) of 50 percent, with formal echocardiography being scheduled for late 2025.

Use of an SGLT2 inhibitor in an elderly patient with CKM syndrome and polypharmacy

23 Apr 2025

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

10 Dec 2024

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

29 Nov 2024

Professor Jean-Jacques Kiladjian, Professor of Clinical Pharmacology, Consultant Haematologist, and head of the Clinical Investigation Centre of Hôpital Saint-Louis & Université Paris Cité in Paris, France, discusses the drawbacks of conventional therapy for PV, and how ropeginterferon alfa-2b may support a shift in treatment.

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

29 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Real-world study: FF/UMEC/VI step-up therapy for COPD comparatively more advantageous than BUD/GLY/FORM

Ruxolitinib: The first and only US FDA–approved topical repigmentation treatment for vitiligo

Ruxolitinib: The first and only US FDA–approved topical repigmentation treatment for vitiligo

Gender-neutral HPV vaccination – an important emerging need

Gender-neutral HPV vaccination – an important emerging need

Advancing collaboration in COVID-19 care

Advancing collaboration in COVID-19 care

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

COVID-19 and beyond: Viral infections, preparedness, and long-term impact

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

Protecting the vulnerable: The role of oral antivirals in COVID-19 management

Use of an SGLT2 inhibitor in an elderly patient with CKM syndrome and polypharmacy

Use of an SGLT2 inhibitor in an elderly patient with CKM syndrome and polypharmacy

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization

Clinical considerations for patients at high risk for progression to severe COVID-19

Clinical considerations for patients at high risk for progression to severe COVID-19

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment

Ropeginterferon alfa-2b supports a shift in polycythaemia vera treatment